222 related articles for article (PubMed ID: 25636928)
1. Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study.
Zusman O; Farbman L; Tredler Z; Daitch V; Lador A; Leibovici L; Paul M
Clin Microbiol Infect; 2015 Jan; 21(1):54-8. PubMed ID: 25636928
[TBL] [Abstract][Full Text] [Related]
2. Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study.
Teo J; Cai Y; Tang S; Lee W; Tan TY; Tan TT; Kwa AL
PLoS One; 2012; 7(3):e34254. PubMed ID: 22461908
[TBL] [Abstract][Full Text] [Related]
3. Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Ho CM; Ho MW; Liu YC; Toh HS; Lee YL; Liu YM; Huang CC; Lu PL; Liu CE; Chen YH; Ko WC; Tang HJ; Yu KW; Chen YS; Chuang YC; Wang JH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S24-8. PubMed ID: 22749055
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
[TBL] [Abstract][Full Text] [Related]
5. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
6. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes.
Hyle EP; Ferraro MJ; Silver M; Lee H; Hooper DC
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1242-9. PubMed ID: 21029005
[TBL] [Abstract][Full Text] [Related]
7. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.
Patel N; Harrington S; Dihmess A; Woo B; Masoud R; Martis P; Fiorenza M; Graffunder E; Evans A; McNutt LA; Lodise TP
J Antimicrob Chemother; 2011 Jul; 66(7):1600-8. PubMed ID: 21508008
[TBL] [Abstract][Full Text] [Related]
8. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
10. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Eagye KJ; Nicolau DP
Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
[TBL] [Abstract][Full Text] [Related]
11. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review.
Falagas ME; Tansarli GS; Kapaskelis A; Vardakas KZ
Expert Rev Anti Infect Ther; 2013 Jan; 11(1):69-78. PubMed ID: 23428103
[TBL] [Abstract][Full Text] [Related]
14. Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review.
Zequinão T; Telles JP; Gasparetto J; Tuon FF
Rev Soc Bras Med Trop; 2020; 53():e20200413. PubMed ID: 33174959
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
16. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
18. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
McDougall DA; Morton AP; Playford EG
J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714
[TBL] [Abstract][Full Text] [Related]
19. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Wu UI; Chen WC; Yang CS; Wang JL; Hu FC; Chang SC; Chen YC
Int J Infect Dis; 2012 Jan; 16(1):e47-52. PubMed ID: 22055248
[TBL] [Abstract][Full Text] [Related]
20. The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
